Noesis Capital Mangement’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$15.9M Buy
126,232
+11,003
+10% +$1.45M 1.92% 21
2026
Q1
$16.1M Sell
115,229
-34
-0% -$4.76K 2.37% 20
2025
Q4
$14.1M Buy
115,263
+745
+0.7% +$90.5K 2.05% 19
2025
Q3
$12.7M Buy
114,518
+943
+0.8% +$107K 1.97% 20
2025
Q2
$12.6M Buy
113,575
+116
+0.1% +$12.3K 2.19% 19
2025
Q1
$12.7M Sell
113,459
-1,380
-1% -$142K 2.53% 16
2024
Q4
$10.6M Sell
114,839
-1,274
-1% -$115K 2.02% 20
2024
Q3
$9.73M Buy
116,113
+4,425
+4% +$338K 1.93% 21
2024
Q2
$7.66M Buy
111,688
+20
+0% +$1.33K 1.7% 25
2024
Q1
$8.18M Buy
111,668
+5,223
+5% +$402K 1.82% 24
2023
Q4
$8.62M Sell
106,445
-1,408
-1% -$110K 2.03% 22
2023
Q3
$8.08M Buy
107,853
+507
+0.5% +$39K 2.12% 22
2023
Q2
$8.27M Buy
107,346
+118
+0.1% +$9.41K 2.04% 24
2023
Q1
$8.9M Buy
107,228
+4,325
+4% +$358K 2.25% 18
2022
Q4
$8.83M Sell
102,903
-4,201
-4% -$333K 2.51% 16
2022
Q3
$6.61M Sell
107,104
-493
-0.5% -$31.1K 2% 22
2022
Q2
$6.65M Sell
107,597
-1,622
-1% -$100K 1.97% 23
2022
Q1
$6.49M Sell
109,219
-1,099
-1% -$70.3K 1.56% 25
2021
Q4
$8.01M Sell
110,318
-15,554
-12% -$1.07M 1.61% 26
2021
Q3
$8.79M Buy
125,872
+1,699
+1% +$119K 1.72% 25
2021
Q2
$8.52M Buy
124,173
+315
+0.3% +$21K 1.74% 24
2021
Q1
$8.01M Sell
123,858
-3,440
-3% -$222K 1.8% 26
2020
Q4
$7.42M Sell
127,298
-3,230
-2% -$195K 1.83% 23
2020
Q3
$8.25M Sell
130,528
-2,882
-2% -$200K 2.34% 22
2020
Q2
$10.3M Sell
133,410
-6,241
-4% -$478K 3.25% 13
2020
Q1
$10.4M Buy
139,651
+373
+0.3% +$25.8K 3.84% 6
2019
Q4
$9.05M Buy
139,278
+874
+0.6% +$56.9K 2.52% 17
2019
Q3
$8.77M Buy
138,404
+931
+0.7% +$60.9K 2.84% 17
2019
Q2
$9.29M Buy
137,473
+926
+0.7% +$60.9K 3.16% 14
2019
Q1
$8.88M Buy
136,547
+37,112
+37% +$2.47M 3.21% 13
2018
Q4
$6.22M Buy
99,435
+1,549
+2% +$108K 2.52% 19
2018
Q3
$7.56M Buy
97,886
+4,781
+5% +$361K 2.65% 18
2018
Q2
$6.6M Sell
93,105
-9,742
-9% -$688K 2.42% 19
2018
Q1
$7.75M Buy
102,847
+2,528
+3% +$201K 2.87% 15
2017
Q4
$7.19M Sell
100,319
-1,705
-2% -$129K 2.59% 15
2017
Q3
$8.27M Sell
102,024
-1,724
-2% -$132K 3.1% 11
2017
Q2
$7.34M Sell
103,748
-2,107
-2% -$140K 2.81% 14
2017
Q1
$7.19M Sell
105,855
-2,284
-2% -$161K 2.74% 15
2016
Q4
$7.74M Buy
108,139
+40,029
+59% +$2.98M 3.23% 8
2016
Q3
$5.39M Buy
68,110
+1,585
+2% +$129K 2.32% 21
2016
Q2
$5.55M Buy
66,525
+726
+1% +$64.4K 2.47% 17
2016
Q1
$6.04M Buy
65,799
+827
+1% +$74.6K 2.75% 15
2015
Q4
$6.58M Buy
64,972
+1,655
+3% +$172K 3.12% 11
2015
Q3
$6.22M Sell
63,317
-6,070
-9% -$674K 3.29% 13
2015
Q2
$8.12M Sell
69,387
-776
-1% -$84.8K 3.5% 5
2015
Q1
$6.88M Buy
70,163
+715
+1% +$72.6K 2.85% 11
2014
Q4
$6.55M Buy
69,448
+6,995
+11% +$723K 2.74% 14
2014
Q3
$6.65M Sell
62,453
-3,411
-5% -$334K 2.89% 11
2014
Q2
$5.46M Buy
65,864
+58,048
+743% +$4.52M 2.47% 15
2014
Q1
$554K Buy
7,816
+1,888
+32% +$148K 0.27% 78
2013
Q4
$445K Sell
5,928
-3,121
-34% -$217K 0.22% 82
2013
Q3
$569K Hold
9,049
0.3% 77
2013
Q2
$464K Buy
+9,049
New +$472K 0.25% 85

Other funds holding GILD

Noesis Capital Mangement's GILD Position: Q2 2026 in Review

Noesis Capital Mangement increased its Gilead Sciences (GILD) stake by 9.5% in Q2 2026, buying an estimated $1.45M and bringing the position to 126,232 shares worth $15.9M. The position accounts for 1.92% of the portfolio, ranked #21.

Noesis Capital Mangement first reported a position in GILD in Q2 2013 and has held it in 53 quarters since. The position peaked at $16.1M in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Noesis Capital Mangement held 126,232 shares of Gilead Sciences worth $15.9M as of Q2 2026.
  • Noesis Capital Mangement bought 11,003 Gilead Sciences shares in Q2 2026, an estimated $1.45M.
  • Gilead Sciences made up 1.92% of Noesis Capital Mangement's portfolio in Q2 2026, its #21 holding.
  • Noesis Capital Mangement first reported a position in Gilead Sciences in Q2 2013 and has held it in 53 quarters since.
  • Noesis Capital Mangement's Gilead Sciences position peaked at $16.1M in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Noesis Capital Mangement's 13F filing for Q2 2026, filed 4 Aug 2026.